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Abstract Currently, no consensus exists on the best method
for tumor quantification in prostate cancer (PCA), and its
prognostic value remains controversial. We evaluated how a
newly defined maximum tumor diameter (MTD) might con-
tribute to the prediction of biochemical recurrence (BCR) in a
consecutive series of PCA patients treated with radical pros-
tatectomy (RP). Patients with PCAwho underwent RP with-
out neoadjuvant therapy at a single center were included for
analysis. MTD was defined as the largest diameter of all
identified tumors in all three dimensions (i.e., length, width,
or depth) of the prostate (“Basel technique”). Cox regression
models addressed the association of MTD with BCR in three
risk groups (low risk—prostate-specific antigen (PSA)<
10 ng/ml, pT2, and Gleason score (GS)≤6; intermediate
risk—PSA≥10 and <20 ng/ml and/or pT2 and GS=7; high
risk—PSA>20 ng/ml or pT3 or GS≥8) and whole cohort.
Within a median follow-up of 44 months (interquartile range
(IQR) 23–66), 48 patients (9.4 %) in the intermediate-risk and
high-risk groups experienced BCR. In multivariate Cox re-
gression analysis, PSA, pathological stage (pT stage), GS,
positive surgical margins (PSMs), and MTD>19.5 mm were
independent predictors for BCR (p<0.05). In subgroup anal-
ysis, MTD as a nominal variable (<24.5 and >24.5 mm) was
the only independent predictor of BCR in the intermediate-
risk group (hazard ratio (HR) 9.933, 95 % confidence interval
(CI) 2.070–47.665; p<0.05). MTD is an independent risk
factor of BCR in PC patients after RP. The combination of
the MTD with other well-known prognostic factors after RP
may improve decision-making concerning follow-up intensity
or adjuvant treatment.
Keywords Prostate cancer . Radical prostatectomy .
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Introduction
The value of tumor quantitation for prostate cancer (PCA)
remains controversial. Despite a current lack of consensus on
the appropriate method for tumor volume (TV)/size assess-
ment, reporting of this variable has been suggested by the
International Society of Urological Pathology (ISUP) [1]. The
association of TV/size with prostate-specific antigen (PSA),
Gleason score (GS), pathological stage (pT stage), positive
surgical margins (PSMs), and clinical outcomes was shown in
several previous studies [2–6]. However, the prognostic value
of TV, independent of well-characterized standard clinico-
pathologic features, on biochemical recurrence (BCR) is weak
[7]. Taking into account that higher GS, advanced pT stage
with or without PSMs, and positive lymph node status (LN+)
are powerful predictors of BCR, some studies provide evi-
dence of the independent prognostic value of tumor quantita-
tion on BCR [3–6, 8–10]. The correct prediction of the prob-
ability of BCR is crucial to identify proper timing for adjuvant
treatment [11]. This is even more important in patients with
intermediate risk constellation where oncologic benefits and
adverse events of adjuvant treatment need to be balanced [12].
There is no general consensus on how to best quantify
tumor in radical prostatectomy specimens, as shown in a
survey across 321 pathology laboratories from 15 west Euro-
pean countries [13]. Several methods for tumor quantification
such as TV, maximum tumor diameter (MTD) of the index
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tumor, positive-block ratio estimation, visual estimation, and
others have been described showing association with BCR or
not [1]. The commonly used methods are visual estimation of
TV or MTD of the index tumor. Although estimation of the
MTD is less time consuming and inexpensive, there is no
consensus on how the index tumor should be designated [1].
In a previous, unpublished study, we developed a new method
of assessment of tumor diameter by adding the MTD of all
tumor areas along one line after deduction of the diameter of
tumor tissue overlapping along this line. Review of over 240
radical prostatectomy showed that modified MTD but not the
diameter of the index tumor was a strong independent prog-
nostic marker. Therefore, this method was introduced in our
daily practice. Here, we tested the predictive value of this
newly defined MTD on biochemical recurrence (BCR) in
patients treated with radical prostatectomy (RP). Moreover,
we assessed how this variable might optimally contribute to
BCR prediction together with other pathological features.
Patients and methods
This study was approved by the institutional ethics review
board. All patients (n=661) who were treated with either
transperitoneal or extraperitoneal laparoscopic RP for PCA
between April 2001 and December 2011 at the Department of
Urology, University Hospital Basel, Switzerland, were includ-
ed for analysis. Patients with incomplete clinical data, lost to
follow-up (n=119), or who received neoadjuvant treatment
(n=7) were excluded. Patients with LN+ (n=24), those who
did not reach undetectable PSA level after surgery, or patients
who received immediate androgen deprivation treatment after
RP were excluded as well. The final study population
consisted of 511 patients. PCA was diagnosed by transrectal
ultrasound-guided biopsies.
All specimens were processed at the Institute for Patholo-
gy, University Hospital Basel, Switzerland. Apical and dorso-
lateral margins were examined by frozen section analysis
according to current guidelines of the International Society
of Urological Pathology (ISUP) [14]. Briefly, we used the
cone method for cutting the apex and the base and then
performed sagittal slicing of the cones. After overnight fixa-
tion in 10 % buffered formalin solution, what remained of the
prostate gland was sectioned at 3–4-mm intervals along a
transverse plane from apex to the base. The external surface
had been previously inked. Whole mount tissue slices were
embedded and further processed according to routine proce-
dures. Formalin-fixed and paraffin-embedded (FFPE) whole
mount sections were stained with hematoxylin and eosin
(H&E) and prospectively evaluated by two pathologists inde-
pendently. The principles of how the greatest diameter was
measured are illustrated in Fig. 1. Themaximum diameter was
calculated as the sum of the largest diameter of all tumor areas
along one line, after deducing the length of overlap of tumor
areas along this line. By this method, the maximum tumor
diameter never exceeds the size of the whole prostate. If
tumors were present in consecutive sections at the same
location and orientation, the measurement was performed in
the same manner as described above. The largest measure
estimated in three dimensions (length, width, and depth) was
considered as theMTD.All distances weremeasured on FFPE
sections with a ruler marked with millimeters (Fig. 1).
The predictive value of the MTD for BCR was tested for
the whole cohort and for risk groups based on clinicopatho-
logical features such as preoperative PSA, pT, and final GS.
Low-risk (PSA<10 ng/ml, pT2 and GS≤6), intermediate-risk
(PSA≥10 and <20 ng/ml and/or pT2 and GS 7), and high-risk
(PSA>20 ng/ml or pT3 or GS≥8) groups were composed.
BCRwas defined as a serum PSA concentration of >0.2 ng/ml
in two independent measurements. The date of the first mea-
surement was defined as the date of BCR. Follow-up for
patients who received adjuvant treatment at the time of
PSA≤0.2 ng/ml ended with the day the treatment started.
The cutoff value for MTD that best discriminated low and
high risk for BCR was designated by computing the receiver
operating curves (ROC) and calculating the Youden index.
Due to different clinicopathological features and different
MTD values in each group, this was done for the whole cohort
and the intermediate-risk and high-risk groups.
The comparison of categorical data and continuous vari-
ables was performed using chi-square tests and Mann-
Whitney U tests, respectively. Cox regression multivariate
models were used to identify factors predictive for BCR.
Biochemical recurrence-free survival (BFS) was analyzed by
the Kaplan-Meier method, and survival of different groups
was compared using log-rank tests. All statistical analyses
were performed using the Statistical Package for the Social
Sciences (SPSS, version 21.0; Chicago, IL, USA) for Win-
dows. A two-sided p value <0.05 was considered significant.
Results
Clinicopathologic features
At the time of operation, patients were on the average 63 years
old (interquartile range (IQR) 59–68) and median PSA was
6.68 ng/ml (IQR 4.9–10.3). The most common clinical stage
and Gleason score were T1 (62.4 %) and ≤6 (54.7 %), respec-
tively. Only 37/511 patients (7.3 %) had biopsy GS ≥8 and
3/511 (0.4 %) patients had clinical stage T3. Palpable disease
or biopsy GS 7 was present in 190/511 (37.2 %) and 194/511
(38 %) cases, respectively. According to final pathological
assessment, 79.6% of the patients (n=407) had organ confined
disease. In 67/511 cases (13.1 %), extracapsular extension
(ECE) was diagnosed and 37/511 patients (7.2 %) had seminal
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vesicle infiltration (SVI). Final GS ≤6, 7, and ≥8 was found in
173/511 (33.8 %), 278/511 (54.3 %), and 60/511 (11.9 %)
specimens, respectively. PSMs were found in 122/511 patients
(23.9 %). The median MTD was 20 mm (IQR 12–26 mm)
(Table 1). After median follow-up of 44 months (IQR 24–67),
48 (9.4%) patients hadBCR.Most of BCR (n=38) occurred in
the high-risk group followed by intermediate-risk (n=10)
group. In the lower-risk group, none of patients had BCR.
Association of MTD with biochemical recurrence
The estimated cutoff values for MTD were 19.5 mm (area
under the curve (AUC) 0.763, 95 % confidence interval (CI)
0.702–0.825; p<0.001), 24.5 mm (AUC 0.794, 95 % CI
0.658–0.931; p=0.002), and 27.5 mm (AUC 0.590, 95 % CI
0.486–0.694; p=0.053) for the whole cohort, intermediate-
risk, and high-risk groups, respectively. Patients with higher
MTD than the estimated cutoff value showed a significantly
worse BFS than patients with smaller MTD in the entire
cohort, intermediate-risk, and high-risk groups, respectively
(p<0.05) (Fig. 2).
In multivariate Cox regression analyses, PSA (hazard ratio
(HR) 1.565, 95 % CI 1.090–2.247; p=0.015), pT stage (HR
1.728, 95 % CI 1.183–2.523; p=0.005), final GS (HR 2.294,
95 % CI 1.631–3.226; p<0.001), PSM (HR 2.421, 95 % CI
1.285–4.562; p=0.006), and MTD>19.5 mm (HR 2.850,
95 % CI 1.129–7.195; p=0.027) were independent predictors
for BCR for the whole cohort. In subgroup analysis, MTD>
24.5 mm was the only independent prognostic factor for BCR
in the intermediate-risk group (HR 9.933, 95 % CI 2.070–
47.665; p=0.004), whereas PSA, pTstage, final GS, and PSM
were not associated with BCR (Table 2).
Fig. 1 Largest diameter (dm) measured in the horizontal and vertical
planes. a Largest dm in the horizontal plane including two non-overlap-
ping tumors. b Largest dm in the horizontal plane including two partly
overlapping tumors. c Largest dm in the horizontal plane including
several partly overlapping tumors (largest dm=dm1+dm2). d Largest
dm in the horizontal plane including several non-overlapping tumors
(largest dm=dm1+dm2+dm3). e Largest dm in the vertical plane
including two non-overlapping tumors (largest dm=dm1+dm2+dm3). f
Largest diameter in the horizontal plane including two non-overlapping
tumors. Thick gray double arrows=diameters that define the largest
diameter; thin gray double arrows=tumor diameters including overlap
of individual tumors in one axis; dashed gray arrows=diameters that are
irrelevant for the largest diameter
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Discussion
In this consecutive series of PCA patients treated with RP, we
found that MTD using a novel method of assessment contrib-
utes to the prediction of BCR. For the whole cohort, MTD>
19.5 mm was significantly predictive, and for patients with
intermediate risk constellation, MTD>24.5 mm was the only
independent predictor of BFS.
The most common approach for MTD estimation is to
measure only the largest (index) tumor [8], as it might have
a major impact on BCR [15]. However, the data on measures
of tumor extent in RP remain controversial, as summarized in
Table 3. Recent studies highlighted the frequent PCA
multifocality with the dominant tumor not always
representing all poorly differentiated elements [16]. Thus,
there is no consensus about the final definition of the index
or dominant tumor and, as a consequence, the correct estima-
tion of the MTD [1]. Our method includes measurement of
extension of all identified tumors in three dimensions. Initial
evaluation of the prognostic ability of MTD in terms of BCR
in a series of 464 men showed that tumors <1 cm have longer
BFS (two consecutive detectable PSA values) than tumors
>2 cm [4]. Multivariate analyses revealed that MTD, PSA,
ECE, or LN+ are independent predictors of BCR. This was
confirmed by a study in which the authors found MTD (HR
1.7, p=0.011) and GS to be independent determinants for
BCR (PSA>0.2 ng/ml), although LN+ and PSA were not
included in the multivariate analysis [9]. The most recent
study included 364 patients treated with RP and showed a
strong independent prognostic value of MTD>20 mm for
BCR (HR 3.07, p<0.001) [3]. PSAwas omitted in the analy-
sis. In all referred studies, MTD was defined as a largest
diameter of the largest tumor.
In contrast, in the most recent series consisting of 781
patients, MTD was not significantly associated with BCR
when adjusted for PSM [17]. In contrast, PCA with a MTD
>13 mm (median MTD value) in patients with a preoperative
PSA <10 ng/ml, pT stage ≤pT3a, and GS 3+4=7 and without
PSM was associated with poor BFS. Dvorak et al. concluded
that a larger MTD in these cases might serve as trigger for
adjuvant treatment [17]. Our results confirm this notion, even
though the risk stratification and cutoff value for MTD were
different. Another European study investigated the prognostic
value ofMTD for BCR (PSA>0.1 ng/ml) in 542 PCA patients
treated with RP [18]. Patients were stratified in three risk
groups according to the D’Amico criteria [19]. Univariate
analysis of MTD (continuous variable) revealed a weak asso-
ciation with risk of BCR (HR 1.02) which could not be
detected in the high-risk group. PSM, GS, pT stage, and
multiple tumors were independent prognostic factors in mul-
tivariate analysis. Interestingly, tumor quantity parameters
Table 1 Clinicopathologic characteristics and oncologic outcome
Age (years)
Mean 63
Median 63
IQR 59–68
PSA (ng/ml)
Mean 9.2
Median 6.68
IQR 4.9–10
Clinical stage
T1 319 (62.4 %)
T2 190 (37.2 %)
T3 3 (0.4 %)
Gleason score (biopsy)
≤6 280 (54.7 %)
3+4 152 (29.7)
4+3 42 (8.3 %)
≥8 37 (7.3 %)
Pathological stage
pT2 (organ confined) 407 (79.6 %)
pT3a (extracapsular extension) 67 (13.1 %)
pT3b (seminal vesicle infiltration) 37 (7.2 %)
Gleason score (final)
≤6 173 (33.8 %)
3+4 197 (38.5 %)
4+3 81 (15.8 %)
≥8 60 (11.9 %)
Maximum tumor diameter (mm)
Mean 19.8
Median 20
IQR 12–26
Surgical margins
Negative 389 (76.1 %)
Positive 122 (23.9 %)
Follow-up (months)
Mean 46.7
Median 44
IQR 23–66
Biochemical recurrence (PSA>0.2 ng/ml)
No 463 (90.6 %)
Yes 48 (9.4 %)
IQR interquartile range
Fig. 2 a–c Kaplan-Meier curves depicting biochemical recurrence-free
survival in 511 patients with prostate cancer treated with radical
prostatectomy according to maximum tumor diameter: a all patients
(*p<0.001), b intermediate-risk PCA patients (*p<0.001), and c high-
risk PCA patients (*p=0.025). d, e Corresponding receiver operating
curves depicting predictive value of biochemical recurrence-free
survival: d all patients (AUC 0.763, 95 % CI 0.702–0.825; p<0.001), e
intermediate-risk PCA patients (AUC 0.794, 95 % CI 0.658–0.931; p=
0.002), and f high-risk PCA patients (AUC 0.590, 95 % CI 0.486–0.694;
p=0.053). *log-rank test
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a<19.5 mm 251 203 143 81 28 8 1
>19.5 mm 258 156 90 51 17 7 0
b
<24.5 mm 153 117 80 49 13 7 1
>24.5 mm 65 44 26 12 5 1 0
c
<27.5 mm 95 66 39 26 5 3 1
>27.5 mm 54 21 14 10 4 2 0
d
e
f
No discrimination
MTD
No discrimination
MTD
No discrimination
MTD
Virchows Arch (2014) 465:429–437 433
(MTD and TV) did not provide any additional information
regardless of risk stratification. For high-risk PCA, MTD did
not provide any further information on BCR prediction, as we
found in our study. Although in our study median value in the
whole cohort was smaller (19.5 mm vs. 24 mm), MTDwas an
independent predictor of the BCR.
Another yet less commonly used parameter for tumor
quantitation is TV [13]. The initial evaluation of the predictive
ability of TVon BCR was discouraging. Epstein at al. found
that only GS and PSM are independent predictors for cancer
progression (increase in postoperative PSA, local recurrence,
and/or presence of distant metastases) in patients with organ-
confined disease after RP [20]. Ohori et al. included in the
analysis 478 patients with clinically localized PCA treated
with RP and found ECE and SVI among with GS to be
independent prognostic factors for cancer progression [21].
TV did not have any prognostic value in either study. While
Salomon et al. had similar results in their study, progression
was defined as BCR (PSA>0.2 ng/ml) [22]. In our analysis
LN+ patients were omitted for the multivariate analysis, as its
strong prognostic value on progression and cancer-specific
survival is well established [23]. Also in a recent study on
344 patients from ERSPC (Rotterdam section) with a long
follow-up (mean 96.2 months), the prognostic value of TV
was assessed. Age at RP, GS 4+3=7, and PSMs were predic-
tive for BCR but none of the reported TV-related variables
(TV, relative TV, and TV>0.5 ml) [24].
Another study provided confusing results by analyzing
predictive determinants for PSA failure (≥0.07 ng/ml) in 379
cases after RP [25]. TV was a highly significant and
independent predictor of BCR tested in a multivariate model
with the percentage of Gleason grade 4/5, LN+, and vascular
invasion. Only the largest tumor detected in the specimens
was used for further investigation. Chun et al. published
corresponding data in which PSA, ECE, TV, and percentage
of high-grade Gleason TV (%HGTV) were predictors of BCR
(PSA>0.1 ng/ml) [10]. LN+, SVI, and PSM were included in
the model, but showed no significant association with risk of
BCR. The authors concluded that %HGTV is a powerful
predictor of BCR after RP, confirming previous publications
[25–28]. Yet another study tested the prognostic value of the
percentage of TV (sum of all visually estimated tumor foci in
relation to the specimen on every section) in terms of BCR
(PSA>0.2 ng/ml) [29]. In multivariate analysis, PSA, final
GS, and percent TV were independent predictors of BCR,
whereas PSM, pT stage, and LN+ failed to reach significance.
Our study is limited by its retrospective nature and short
follow-up time. The low number of BCR is at least in part
caused by patients with a high-risk constellation (PSA<
0.2 ng/ml) who already received or rapidly entered into adju-
vant treatment. Furthermore, clinical outcome data on local
recurrence, metastasis, and mortality were not available. Fi-
nally, our cohort contained a high number of organ confined
PCAs (79.6 %), a main prognostic factor even though most of
them had Gleason score ≥7 (72.2 %).
We conclude that MTD assessed by our novel method
might be a useful additional prognostic factor for the predic-
tion of BFS in patients after RP. Especially in patients with
intermediate-risk constellation, MTD may influence decision
making regarding adjuvant treatment.
Table 2 Multivariate Cox re-
gression analysis for determinants
predicting biochemical recurrence
in a whole cohort and patients
with intermediate-risk and high-
risk prostate cancer
p value HR 95 % CI
Whole cohort
PSA 0.015 1.565 1.090–2.247
pT stage 0.005 1.728 1.183–2.523
Gleason score <0.001 2.294 1.631–3.226
Surgical margins 0.006 2.421 1.285–4.562
Maximum tumor diameter (<19.5 vs. >19.5 mm) 0.027 2.850 1.129–7.195
Patients with intermediate-risk prostate cancer
PSA 0.149 1.131 0.957–1.337
pT stage 0.629 1.347 0.402–4.506
Gleason score 0.867 1.099 0.364–3.313
Surgical margins 0.204 0.248 0.029–2.126
Maximum tumor diameter (<24.5 vs. >24.5 mm) 0.004 9.933 2.070–47.665
Patients with high-risk prostate cancer
PSA 0.110 1.014 0.997–1.031
pT stage 0.098 1.333 0.948–1.873
Gleason score <0.001 2.066 1.422–3.002
Surgical margins 0.001 3.916 1.793–8.549
Maximum tumor diameter (<27.5 vs. >27.5 mm) 0.533 1.253 0.617–2.542
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